Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

被引：51

作者：

Mizuno, Y

Yanagisawa, N

Kuno, S

Yamamoto, M

Hasegawa, K

Origasa, H

Kowa, H

机构：

[1] Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan

[2] Kanto Rosai Hosp, Kawasaki, Kanagawa, Japan

[3] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Sect, Kyoto, Japan

[4] Kagawa Prefectural Cent Hosp, Dept Neurol, Takamatsu, Kagawa, Japan

[5] Sagamihara Natl Hosp, Dept Neurol, Sagamihara, Kanagawa, Japan

[6] Toyama Med & Pharmaceut Univ, Fac Med, Div Biostat, Toyama, Japan

[7] Kitasato Univ, Tokyo, Japan

来源：

MOVEMENT DISORDERS | 2003年 / 18卷 / 10期

关键词：

Parkinson's disease; pramipexole; bromocriptine; levodopa; drug comparison; randomized controlled trial (RCT);

D O I：

10.1002/mds.10508

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (1311) group was included to enable determination of the noninferiority of PPX relative to 1311 as the standard treatment. (C) 2003 Movement Disorder Society.

引用

页码：1149 / 1156

页数：8

共 50 条

[21] Helicobacter pylori eradication in Parkinson's disease: A double-blind randomized placebo-controlled study
Tan, A. H.
Lim, S. Y.
Mahadeva, S.
Loke, M. F.
Vadivelu, J. S.
Marras, C.
Fox, H.
Lang, A. E.
[J]. MOVEMENT DISORDERS, 2020, 35 : S422 - S425
[22] Atomoxetine for the treatment of depression in Parkinson's disease: A randomized, double-blind, placebo-controlled study
Weintraub, D.
Mavandadi, S.
Horn, S.
Hurtig, H.
Siderowf, A.
Duda, J.
Stern, M.
[J]. MOVEMENT DISORDERS, 2009, 24 : S286 - S286
[23] A randomized, double-blind, placebo-controlled study of atornoxetine for freezing of gait in Parkinson's disease
Nashatizadeh, M. M.
Jimenez, J. E.
Davidson, A. L.
Jankovic, J.
[J]. MOVEMENT DISORDERS, 2008, 23 (01) : S219 - S219
[24] PLACEBO EFFECT OF MEDICATION COST IN PARKINSON DISEASE: A RANDOMIZED DOUBLE-BLIND STUDY Response
Espay, Alberto J.
Dwivedi, Alok
Lang, Anthony E.
Linke, Michael J.
Szaflarski, Jerzy P.
[J]. NEUROLOGY, 2015, 85 (08) : 742 - 743
[25] Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study
Zhang, Zhen-Xin
Liu, Chun-Feng
Tao, En-Xiang
Shao, Ming
Liu, Yi-Ming
Wang, Jian
Asgharnejad, Mahnaz
Xue, Hai-Bo
Surmann, Erwin
Bauer, Lars
[J]. PARKINSONISM & RELATED DISORDERS, 2017, 44 : 6 - 12
[26] Rapid efficacy of a noradrenergic reuptake inhibitor in depression in advanced Parkinson's disease:: A double-blind, randomized, placebo-controlled study
Devos, D.
Poirot, I.
Dujardin, K.
Duhem, S.
Lucas, B.
Waucquier, N.
Moreau, C.
Bocquillon, P.
Devos, P.
Ajebbar, K.
Thielemans, B.
Cottencin, O.
Thomas, P.
Destee, A.
Bordet, R.
Defebvre, L.
[J]. MOVEMENT DISORDERS, 2007, 22 : S223 - S224
[27] Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind study
Zhang, Z.
Asgharnejad, M.
Xue, H.
Surmann, E.
Bauer, L.
[J]. MOVEMENT DISORDERS, 2016, 31 : S609 - S610
[28] Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease
Hauser, Robert A.
Schapira, Anthony H. V.
Rascol, Olivier
Barone, Paolo
Mizuno, Yoshikuni
Salin, Laurence
Haaksma, Monika
Juhel, Nolwenn
Poewe, Werner
[J]. MOVEMENT DISORDERS, 2010, 25 (15) : 2542 - 2549
[29] A double-blind, single-dose crossover study of the effects of pramipexole, pergolide, and placebo on tremor and UPDRS (III) in Parkinson's disease
Navan, P
Findley, LJ
Pearce, RKB
Jeffs, J
Bain, PG
[J]. NEUROLOGY, 2002, 58 (07) : A469 - A469
[30] Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
Alvarez-Nemegyei, J
Cobarrubias-Cobos, A
Escalante-Triay, F
Sosa-Munoz, J
Miranda, JM
Jara, LJ
[J]. LUPUS, 1998, 7 (06) : 414 - 419

← 1 2 3 4 5 →